Emerging evidence has strongly implicated NFκB activation in ibrutinib-resistant CLL (3), emphasizing the importance of therapeutics which directly target NFκB proteins for relapsed and/or refractory patients. Here, NFKB1 is linked to B-cell chronic lymphocytic leukemia.